Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
48
FULC Quote, Financials, Valuation and Earnings
Last price:
$8.76
Seasonality move
:
23.58%
Day range:
$8.68 - $9.29
52-week range:
$2.32 - $12.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.39x
Volume:
821.2K
Avg. volume:
827.1K
1-year change:
149.57%
Market cap:
$474.1M
Revenue:
$80M
EPS (TTM):
-$1.18
Analysts' Opinion
-
Consensus RatingFulcrum Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.56, Fulcrum Therapeutics, Inc. has an estimated upside of 66.16% from its current price of $8.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 31.51% downside risk from its current price of $8.76.
Fair Value
-
According to the consensus of 7 analysts, Fulcrum Therapeutics, Inc. has 66.16% upside to fair value with a price target of $14.56 per share.
FULC vs. S&P 500
-
Over the past 5 trading days, Fulcrum Therapeutics, Inc. has underperformed the S&P 500 by -22.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Fulcrum Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Fulcrum Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Fulcrum Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Fulcrum Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Fulcrum Therapeutics, Inc. reported earnings per share of -$0.31.
Enterprise value:
280.4M
EV / Invested capital:
1.37x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
-4.64x
Price / Operating cash flow:
60.70x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.3M
Return On Assets:
-29%
Net Income Margin (TTM):
--
Return On Equity:
-31.15%
Return On Invested Capital:
-30.08%
Operating Margin:
65.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.6M | $80.9M | -- | -- | -- | |
| Gross Profit | $362K | $79.1M | -$1.3M | -$400K | -$300K | |
| Operating Income | -$110.7M | -$28.4M | -$81.5M | -$23.1M | -$21.9M | |
| EBITDA | -$108.4M | -$26.6M | -$80.2M | -$22.7M | -$21.6M | |
| Diluted EPS | -$1.69 | -$0.31 | -$1.18 | -$0.35 | -$0.31 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $246.2M | $227.7M | $262.5M | $267.5M | $205.9M | |
| Total Assets | $255.5M | $247.8M | $278.9M | $279M | $214.9M | |
| Current Liabilities | $20.6M | $14.7M | $14.1M | $14.5M | $11.6M | |
| Total Liabilities | $24.9M | $26.4M | $23.4M | $21.7M | $16.5M | |
| Total Equity | $230.6M | $221.4M | $255.5M | $257.3M | $198.4M | |
| Total Debt | -- | $11.5M | $9.1M | $7M | $4.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$87.5M | -$8.6M | -$60M | -$19.1M | -$14.2M | |
| Cash From Investing | -$91.4M | $48.3M | $34M | $4.4M | $18.6M | |
| Cash From Financing | $118.1M | $3M | $448K | $635K | $64K | |
| Free Cash Flow | -$88.1M | -$8.7M | -$60.4M | -$19.1M | -$14.3M | |
FULC
Sector
Market Cap
$474.1M
$28.4M
Price % of 52-Week High
71.86%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
0.02%
-1.32%
1-Year Price Total Return
149.57%
-22.19%
Beta (5-Year)
3.172
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$10.27
200-day SMA
Buy
Level
$6.58
Bollinger Bands (100)
Buy
Level
6.81 - 9.55
Chaikin Money Flow
Sell
Level
-37.8M
20-day SMA
Sell
Level
$9.62
Relative Strength Index (RSI14)
Sell
Level
42.66
ADX Line
Sell
Level
24.95
Williams %R
Buy
Level
-91.2234
50-day SMA
Sell
Level
$9.31
MACD (12, 26)
Buy
Level
0.20
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
213.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.9723)
Buy
CA Score
(Annual)
Level (1.2503)
Sell
Beneish M-Score
(Annual)
Level (20.5767)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.9209)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, FULC has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The FULC average analyst price target in the past 3 months is $14.56.
-
Where Will Fulcrum Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Fulcrum Therapeutics, Inc. share price will rise to $14.56 per share over the next 12 months.
-
What Do Analysts Say About Fulcrum Therapeutics, Inc.?
Analysts are divided on their view about Fulcrum Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Fulcrum Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Fulcrum Therapeutics, Inc.'s Price Target?
The price target for Fulcrum Therapeutics, Inc. over the next 1-year time period is forecast to be $14.56 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is FULC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Fulcrum Therapeutics, Inc. is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of FULC?
You can purchase shares of Fulcrum Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Fulcrum Therapeutics, Inc. shares.
-
What Is The Fulcrum Therapeutics, Inc. Share Price Today?
Fulcrum Therapeutics, Inc. was last trading at $8.76 per share. This represents the most recent stock quote for Fulcrum Therapeutics, Inc.. Yesterday, Fulcrum Therapeutics, Inc. closed at $8.76 per share.
-
How To Buy Fulcrum Therapeutics, Inc. Stock Online?
In order to purchase Fulcrum Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get FULC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
FULC
Sector
P/E ratio
--
23.66x
PEG ratio
-0.03x
-0.01x
P/B ratio
2.39x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
FULC
Sector
Revenue growth
-100%
4.85%
Earnings growth
9.95%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.29
-$0.20
Profitability
FULC
Sector
Profitability FY 2024
$78.4M
$3.6M
Return on invested capital
-30.08%
-30.98%
Return on assets
-29%
-27.62%
Return on equity
-31.15%
-36.69%
Earnings Date
Last Earnings Date
Oct
29
Next Earnings Date
Feb
24
Estimated Next Earnings Date
Jan
28
Balance Sheet
FULC
Sector
Total cash
$200.6M
$27.2M
Short term investments
$182.8M
$25.7M
Total assets
$260.7M
$79.9M
Long term debt
$4.7M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
